By all accounts, Winston Churchill was an alcoholic and yet he functioned at a very high level until the end of his long life. Yet does everyone who uses a potentially addictive substance become addicted? Our guest today is Dr. Berta Madras who serves as the Deputy Director of Demand Reduction in the White House office of National Drug Control Policy. Prior to this government post, she was Professor of Psychobiology in the Department of Psychiatry at Harvard Medical School. She is an expert on drug addiction and has authored over 130 papers and book chapters as well as receiving 16 patents.
War on Drugs: Myths of abuse and addiction
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Overview
By all accounts, Winston Churchill was an alcoholic and yet he functioned at a very high level until the end of his long life. Yet does everyone who uses a potentially addictive substance become addicted? Our guest today is Dr. Berta Madras who serves as the Deputy Director of Demand Reduction in the White House office of National Drug Control Policy. Prior to this government post, she was Professor of Psychobiology in the Department of Psychiatry at Harvard Medical School. She is an expert on drug addiction and has authored over 130 papers and book chapters as well as receiving 16 patents.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Partnering with Patients: Building Effective Communication and Support in HF Care
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?